Biological
BBV152 COVID-19 vaccine clinical trials
Also written COVAXIN and BBV152.
- studies test it
- 8
- open now
- 0
- in phase 3
- 5
- first study started
- 2020
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
Bharat Biotech International Limited (6) · Tan Tock Seng Hospital (1) · Ocugen (1)
Often tested with
Tested in the same studies.
NVX-CoV2373 adjuvated lipid nanoparticle (1) · ChAdOx1 nCoV-19 (1)
Studies
Open first, then newest update. How each study uses BBV152 COVID-19 vaccine is read from its arms, and is right about nine times in ten.
Testing it · 8
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]CompletedPhase 4Tan Tock Seng HospitalNCT05142319Written as COVAXIN
- Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy AdultsStatus unknownPhase 2/3OcugenNCT05258669Written as BBV152
- BBV152/BBV154 Heterologus Prime-Boost StudyCompletedPhase 2Bharat Biotech International LimitedNCT05639998Written as COVAXIN(BBV152)
- Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster DoseCompletedPhase 3Bharat Biotech International LimitedNCT05567471Written as BBV154 Intranasal Vaccine
- Phase III Study of BBV154 Intranasal Vaccine in Healthy VolunteersStatus unknownPhase 3Bharat Biotech International LimitedNCT05522335Written as BBV154(Intranasal) & covaxin
- Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19CompletedPhase 1Bharat Biotech International LimitedNCT04751682Written as BBV154 Vaccine
- COVAXIN in a Pediatric CohortCompletedPhase 2/3Bharat Biotech International LimitedNCT04918797Written as COVAXIN
- An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult VolunteersStatus unknownPhase 3Bharat Biotech International LimitedNCT04641481Written as BBV152
Codes
What other systems call BBV152 COVID-19 vaccine · ClinicalTrials.gg INT001844
- MeSH (NLM) C000722386BBV152 COVID-19 vaccineOne source NLM
- UNII (FDA) 76JZE5DSN6BBV-152 ANTIGENConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722386 | BBV152 COVID-19 vaccine | One source NLM |
| UNII (FDA) | 76JZE5DSN6 | BBV-152 ANTIGEN | Confirmed FDA, NLM |
Also registered as bbv-152 antigen adjuvated with algel-imdg (UNII 76QBM68XR2).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.